Lymphocyte Cytosolic Protein 2 is a Novel Prognostic Marker in Lung Adenocarcinoma

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2021 Nov 24

PMID 34816740

Citations 8

Authors

Yishan Huo

Kainan Zhang

Songtao Han

Yangchun Feng

Yongxing Bao

Affiliations

Soon will be listed here.

Abstract

Objective: Lymphocyte cytosolic protein 2 (LCP2) is often ectopically expressed in various human tumors. However, the clinical significance and role of LCP2 in lung adenocarcinoma (LUAD) remain unclear. This study explored the prognostic significance of LCP2 in LUAD patients.

Methods: LCP2 expression in LUAD tissues was analyzed using data from The Cancer Genome Atlas and Genotype-Tissue Expression databases. Western blotting was employed to detect LCP2 expression in LUAD. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were performed to explore signaling pathways mediated by LCP2 co-regulatory genes. Immunohistochemistry was used to examine levels of LCP2 and programmed death ligand 1 (PD-L1) in 68 LUAD patients. Associations between LCP2 expression and clinicopathological features, prognoses, and PD-L1 levels among the LUAD in-patients were analyzed.

Results: Among the 68 LUAD in-patients, LCP2 expression was correlated with clinical stage and lymph node metastasis. LUAD patients with high LCP2 expression were associated with increased overall survival. LCP2 expression may be associated with an enrichment of several immune functions. Moreover, our immunohistochemistry results demonstrated that LCP2 expression was positively correlated with PD-L1 expression in LUAD tissues.

Conclusions: In the study, LCP2 was found to be a favorable prognostic biomarker in LUAD patients.

Citing Articles

Integrated analysis of single-cell and bulk-RNA sequencing for the cellular senescence in prognosis of lung adenocarcinoma.

Yu F, Zhang L, Zhang X, Zeng J, Lai F Sci Rep. 2025; 15(1):1442.

PMID: 39789322 PMC: 11717922. DOI: 10.1038/s41598-025-85758-w.

Identification of useful biomolecular markers in kidney renal clear cell carcinoma: an in silico and in vitro analysis-based study.

Sheikh K, Memon K, Usman H, Abdel-Maksoud M, Ullah S, N Almanaa T Am J Transl Res. 2023; 15(9):5574-5593.

PMID: 37854221 PMC: 10579006.

Using bioinformatics and systems biology methods to identify the mechanism of interaction between COVID-19 and nonalcoholic fatty liver disease.

Dong W, Jin Y, Shi H, Zhang X, Chen J, Jia H Medicine (Baltimore). 2023; 102(23):e33912.

PMID: 37335656 PMC: 10256337. DOI: 10.1097/MD.0000000000033912.

ABI3BP is a prognosis biomarker related with clinicopathological features and immunity infiltration of lung tumor.

Feng Y, Han X, Zhang Z, Qiao H, Tang H Front Genet. 2023; 13:1085785.

PMID: 36744181 PMC: 9894588. DOI: 10.3389/fgene.2022.1085785.

Title: Bioinformatic Identification of Genes Involved in Diabetic Nephropathy Fibrosis and their Clinical Relevance.

Bai Y, Ma L, Deng D, Tian D, Liu W, Diao Z Biochem Genet. 2023; 61(4):1567-1584.

PMID: 36715962 DOI: 10.1007/s10528-023-10336-6.

References

Maltzman J, Kovoor L, Clements J, Koretzky G . Conditional deletion reveals a cell-autonomous requirement of SLP-76 for thymocyte selection. J Exp Med. 2005; 202(7):893-900. PMC: 2213170. DOI: 10.1084/jem.20051128. View

Bianchini G, Balko J, Mayer I, Sanders M, Gianni L . Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016; 13(11):674-690. PMC: 5461122. DOI: 10.1038/nrclinonc.2016.66. View

Chen S, Crabill G, Pritchard T, McMiller T, Wei P, Pardoll D . Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019; 7(1):305. PMC: 6858680. DOI: 10.1186/s40425-019-0770-2. View

Siggs O, Miosge L, Daley S, Asquith K, Foster P, Liston A . Quantitative reduction of the TCR adapter protein SLP-76 unbalances immunity and immune regulation. J Immunol. 2015; 194(6):2587-95. PMC: 4355390. DOI: 10.4049/jimmunol.1400326. View

Zak K, Grudnik P, Guzik K, Zieba B, Musielak B, Domling A . Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. 2016; 7(21):30323-35. PMC: 5058683. DOI: 10.18632/oncotarget.8730. View

Zhang J, Wang L, Xu X, Li X, Guan W, Meng T . Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer. Front Oncol. 2020; 10:1787. PMC: 7530237. DOI: 10.3389/fonc.2020.01787. View

Wang Z, Peng M . A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8 T cells. Sci Rep. 2021; 11(1):9164. PMC: 8080722. DOI: 10.1038/s41598-021-88676-9. View

Dezorella N, Katz B, Shapiro M, Polliack A, Perry C, Herishanu Y . SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. Haematologica. 2016; 101(12):1553-1562. PMC: 5479607. DOI: 10.3324/haematol.2015.139154. View

Navas V, Cuche C, Alcover A, Di Bartolo V . Serine Phosphorylation of SLP76 Is Dispensable for T Cell Development but Modulates Helper T Cell Function. PLoS One. 2017; 12(1):e0170396. PMC: 5249077. DOI: 10.1371/journal.pone.0170396. View

10.

Yan Z, Luo H, Xie B, Tian T, Li S, Chen Z . Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis. Nat Commun. 2021; 12(1):308. PMC: 7804203. DOI: 10.1038/s41467-020-20577-3. View

11.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

12.

Sommers C, Menon R, Grinberg A, Zhang W, Samelson L, Love P . Knock-in mutation of the distal four tyrosines of linker for activation of T cells blocks murine T cell development. J Exp Med. 2001; 194(2):135-42. PMC: 2193454. DOI: 10.1084/jem.194.2.135. View

13.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

14.

Koretzky G, Abtahian F, Silverman M . SLP76 and SLP65: complex regulation of signalling in lymphocytes and beyond. Nat Rev Immunol. 2006; 6(1):67-78. DOI: 10.1038/nri1750. View

15.

Chu S, Wang H, Yu M . A putative molecular network associated with colon cancer metastasis constructed from microarray data. World J Surg Oncol. 2017; 15(1):115. PMC: 5477128. DOI: 10.1186/s12957-017-1181-9. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Maj T, Wang W, Crespo J, Zhang H, Wang W, Wei S . Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol. 2017; 18(12):1332-1341. PMC: 5770150. DOI: 10.1038/ni.3868. View

18.

Cha J, Chan L, Li C, Hsu J, Hung M . Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019; 76(3):359-370. PMC: 6981282. DOI: 10.1016/j.molcel.2019.09.030. View

19.

Bremnes R, Busund L, Kilvaer T, Andersen S, Richardsen E, Paulsen E . The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(6):789-800. DOI: 10.1016/j.jtho.2016.01.015. View

20.

Moncayo G, Grzmil M, Smirnova T, Zmarz P, Huber R, Hynx D . SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. Neuro Oncol. 2018; 20(5):621-631. PMC: 5892144. DOI: 10.1093/neuonc/noy008. View